AR078733A1 - Compuestos heterociclicos fusionados como moduladores del receptor de orexina - Google Patents

Compuestos heterociclicos fusionados como moduladores del receptor de orexina

Info

Publication number
AR078733A1
AR078733A1 ARP100103876A ARP100103876A AR078733A1 AR 078733 A1 AR078733 A1 AR 078733A1 AR P100103876 A ARP100103876 A AR P100103876A AR P100103876 A ARP100103876 A AR P100103876A AR 078733 A1 AR078733 A1 AR 078733A1
Authority
AR
Argentina
Prior art keywords
group
substituted
unsubstituted
alkyl
members
Prior art date
Application number
ARP100103876A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR078733A1 publication Critical patent/AR078733A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
ARP100103876A 2009-10-23 2010-10-22 Compuestos heterociclicos fusionados como moduladores del receptor de orexina AR078733A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25452909P 2009-10-23 2009-10-23

Publications (1)

Publication Number Publication Date
AR078733A1 true AR078733A1 (es) 2011-11-30

Family

ID=43430851

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103876A AR078733A1 (es) 2009-10-23 2010-10-22 Compuestos heterociclicos fusionados como moduladores del receptor de orexina

Country Status (9)

Country Link
US (1) US8680275B2 (enExample)
EP (1) EP2491034B1 (enExample)
JP (1) JP5847087B2 (enExample)
AR (1) AR078733A1 (enExample)
CL (1) CL2010001159A1 (enExample)
PE (1) PE20110296A1 (enExample)
TW (1) TW201121966A (enExample)
UY (1) UY32968A (enExample)
WO (1) WO2011050200A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2012085857A1 (en) * 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
WO2013050938A1 (en) * 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
UA112317C2 (uk) 2011-11-08 2016-08-25 Актеліон Фармасьютікалз Лтд Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
CN104220065A (zh) 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
PL2855453T3 (pl) 2012-06-04 2017-05-31 Actelion Pharmaceuticals Ltd. Pochodne benzimidazoloproliny
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
CN103012293A (zh) * 2012-12-13 2013-04-03 同济大学 一种抗失眠药物mk-4305中间体的合成方法
WO2014113303A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. 4-fluoropiperidine orexin receptor antagonists
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
KR102306951B1 (ko) * 2013-07-10 2021-10-01 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 융합된 피페리딘 아미드
EP3077391B1 (en) 2013-12-04 2018-08-15 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
EP3107907A1 (en) * 2014-02-20 2016-12-28 Takeda Pharmaceutical Company Limited Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016085784A1 (en) * 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
MX2017016876A (es) 2015-06-23 2018-04-10 Kissei Pharmaceutical Derivado de pirazol o sal farmaceuticamente aceptable del mismo.
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
WO2017088759A1 (en) * 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SMT202200323T1 (it) 2016-02-12 2022-09-14 Astrazeneca Ab Piperidine alo-sostituite come modulatori del recettore di oressina
HUE058759T2 (hu) 2016-03-10 2022-09-28 Janssen Pharmaceutica Nv Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
JP6654614B2 (ja) * 2016-12-21 2020-02-26 キッセイ薬品工業株式会社 Ｔｒｐｍ８阻害薬
IL270274B (en) 2017-05-03 2022-08-01 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
WO2019063605A1 (en) 2017-09-28 2019-04-04 Boehringer Ingelheim International Gmbh NOVEL N- (2,2-DIFLUOROETHYL) -N - [(PYRIMIDINYLAMINO) PROPANYL] ARYLCARBOXAMIDES

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375897B1 (en) 2000-02-14 2002-04-23 Ansys Technologies, Inc. Urine collection cup
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
EP1705179A1 (en) 2001-06-28 2006-09-27 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
US6455722B1 (en) 2001-06-29 2002-09-24 Pabu Services, Inc. Process for the production of pentaerythritol phosphate alcohol
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
CN1556705B (zh) 2002-07-09 2010-04-28 埃科特莱茵药品有限公司 7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
KR20050043988A (ko) 2002-10-11 2005-05-11 액테리온 파마슈티칼 리미티드 설포닐아미노-아세트산 유도체 및 오렉신 수용체길항제로서 이들의 용도
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
CA2587141A1 (en) 2004-11-24 2006-06-01 Pfizer Inc. Octahydropyrrolo[3,4-c]pyrrole derivatives
BRPI0611439A2 (pt) 2005-05-13 2010-09-08 Lexicon Pharmaceuticals Inc compostos multicìclicos e métodos para uso dos mesmos
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
JP2009506061A (ja) * 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
AU2007245037A1 (en) 2006-03-29 2007-11-08 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
JP2009543790A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド ２−置換プロリンビス−アミドオレキシン受容体アンタゴニスト
WO2008008517A2 (en) * 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
DK2049529T3 (da) 2006-07-14 2010-11-29 Merck Sharp & Dohme Substituerede diazepan-orexin-receptor- antagonister
EP2066674B1 (en) 2006-09-18 2010-06-30 F.Hoffmann-La Roche Ag Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents
WO2008067121A2 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP2150114A4 (en) 2007-05-18 2012-01-18 Merck Sharp & Dohme OXO-BRIDGED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
BRPI0815079A2 (pt) 2007-08-15 2015-02-03 Actelion Pharmaceuticals Ltd Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
AU2008319419A1 (en) 2007-10-29 2009-05-07 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
NZ586913A (en) 2007-12-21 2012-06-29 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
EP2349270B1 (en) 2008-10-21 2015-09-09 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
AU2009307915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739927A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8669272B2 (en) 2008-10-21 2014-03-11 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
US8357709B2 (en) 2008-10-21 2013-01-22 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
AU2009308982A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
US8399494B2 (en) 2008-10-30 2013-03-19 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
NZ592544A (en) 2008-10-30 2013-01-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists
JP2012509911A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
EP2358711A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP2012509912A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
AR074426A1 (es) 2008-12-02 2011-01-19 Glaxo Group Ltd Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds

Also Published As

Publication number Publication date
EP2491034B1 (en) 2013-12-18
US8680275B2 (en) 2014-03-25
HK1175461A1 (en) 2013-07-05
US20120202783A1 (en) 2012-08-09
JP2013508404A (ja) 2013-03-07
UY32968A (es) 2011-04-29
CL2010001159A1 (es) 2011-05-06
PE20110296A1 (es) 2011-05-21
TW201121966A (en) 2011-07-01
JP5847087B2 (ja) 2016-01-20
EP2491034A1 (en) 2012-08-29
WO2011050200A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
AR078733A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de orexina
AR078731A1 (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
AR078732A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de la orexina
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2012015120A (es) Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica.
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
PE20160540A1 (es) Inhibidores de bromodominios
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR066583A1 (es) Derivados de 3,3-espiroindolinona
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
AR078786A1 (es) Derivados de la cromenona
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
PE20130346A1 (es) Compuestos heterociclicos fusionados
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure